{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:15:09Z","timestamp":1792782909770,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006593","name":"Board of Research in Nuclear Sciences","doi-asserted-by":"publisher","award":["202203HLC19RP07105-BRNS"],"award-info":[{"award-number":["202203HLC19RP07105-BRNS"]}],"id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPIG-2023-0000845"],"award-info":[{"award-number":["IIRPIG-2023-0000845"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manipal Academy of Higher Education, Manipal","id":[{"id":"https:\/\/ror.org\/02xzytt36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The ubiquitin\u2013proteasome system (UPS) is an important regulator of numerous cellular pathways, including DNA repair, protein degradation, the cell cycle, and signal transduction. UBE2C, a member of the ubiquitin-conjugating enzyme family, facilitates the ubiquitination of essential cellular regulators. Notably, UBE2C is consistently overexpressed in breast, lung, brain, hepatocellular, and ovarian carcinomas. Increased UBE2C expression is associated with tumour aggressiveness, genomic instability, epithelial-to-mesenchymal transition, and resistance to chemotherapy and radiotherapy. Our review explores the mechanistic involvement of UBE2C in diverse cancers, with a particular focus on its involvement in DNA damage repair mediated by the anaphase-promoting complex (APC\/C). Furthermore, the regulatory effects of miR-381, miR-503, and miR-205 on UBE2C expression were examined, highlighting the promising prospects of these miRNAs for targeted cancer therapy. The involvement of UBE2C in different cancer hallmarks underscores its potential as a biomarker and therapeutic target. A comprehensive understanding of its mechanistic involvement in cell cycle regulation and DNA repair will further enhance its application in diagnostics, personalised medicine, and precision medicine.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>UBE2C acts as a central regulator of tumour progression by coordinating cell-cycle control, oncogenic signalling, DNA damage repair, and therapy resistance. Dysregulated UBE2C expression promotes cancer cell proliferation, survival, genome maintenance, and treatment resistance, whereas its inhibition through miRNAs, RNAi, or pharmacological agents induces cell-cycle arrest, apoptosis, and enhanced therapeutic sensitivity, supporting UBE2C as an attractive target for cancer therapy. Created with BioRender.com.<\/jats:p>","DOI":"10.1007\/s10565-026-10230-y","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:25:27Z","timestamp":1784561127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UBE2C at the crossroads of cell cycle regulation and DNA damage response in cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Sayandrila","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amoolya","family":"Kandettu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-8098","authenticated-orcid":false,"given":"Sanjiban","family":"Chakrabarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"10","key":"10230_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152557","volume":"215","author":"W Alafate","year":"2019","unstructured":"Alafate W, Zuo J, Deng Z, Guo X, Wu W, Zhang W, et al. Combined elevation of AURKB and UBE2C predicts severe outcomes and therapy resistance in glioma. Pathol Res Pract. 2019;215(10):152557.","journal-title":"Pathol Res Pract"},{"issue":"4","key":"10230_CR2","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200390","volume":"11","author":"F Aliabadi","year":"2021","unstructured":"Aliabadi F, Sohrabi B, Mostafavi E, Pazoki-Toroudi H, Webster TJ. Ubiquitin\u2013proteasome system and the role of its inhibitors in cancer therapy. Open Biol. 2021;11(4):200390.","journal-title":"Open Biol"},{"issue":"2","key":"10230_CR3","volume":"14","author":"AB Awan","year":"2025","unstructured":"Awan AB, Osman MJA, Khan OM. Ubiquitination enzymes in cancer, cancer immune evasion, and potential therapeutic opportunities. Cells. 2025;14(2):69.","journal-title":"Cells"},{"issue":"27","key":"10230_CR4","doi-asserted-by":"crossref","first-page":"14231","DOI":"10.1074\/jbc.M116.731398","volume":"291","author":"S Bajaj","year":"2016","unstructured":"Bajaj S, Alam SK, Roy KS, Datta A, Nath S, Roychoudhury S. E2 ubiquitin-conjugating enzyme, UBE2C gene, is reciprocally regulated by wild-type and gain-of-function mutant p53. J Biol Chem. 2016;291(27):14231\u201347.","journal-title":"J Biol Chem"},{"issue":"2","key":"10230_CR5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cell.2008.05.043","volume":"134","author":"F Bassermann","year":"2008","unstructured":"Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell. 2008;134(2):256\u201367.","journal-title":"Cell"},{"issue":"52","key":"10230_CR6","doi-asserted-by":"crossref","first-page":"20982","DOI":"10.1073\/pnas.1320302111","volume":"110","author":"M Bohgaki","year":"2013","unstructured":"Bohgaki M, Bohgaki T, El Ghamrasni S, Srikumar T, Maire G, Panier S, et al. RNF168 ubiquitylates 53BP1 and controls its response to DNA double-strand breaks. Proc Natl Acad Sci U S A. 2013;110(52):20982\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10230_CR7","unstructured":"Brown NG, Cho SE, Schulman BA. Crystal Structure of E2 Complex. Proceedings of the National Academy of Sciences of the United States of America. 2015."},{"issue":"6","key":"10230_CR8","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.7150\/jca.92473","volume":"15","author":"D Cai","year":"2024","unstructured":"Cai D, Tian F, Wu M, Tu J, Wang Y. UBE2C is a diagnosis and therapeutic biomarker involved in immune infiltration of cancers including lung adenocarcinoma. J Cancer. 2024;15(6):1701\u201317.","journal-title":"J Cancer"},{"issue":"7557","key":"10230_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature14471","volume":"522","author":"L Chang","year":"2015","unstructured":"Chang L, Zhang Z, Yang J, McLaughlin SH, Barford D. Atomic structure of the APC\/C and its mechanism of protein ubiquitination. Nature. 2015June 25;522(7557):450\u20134.","journal-title":"Nature."},{"issue":"3","key":"10230_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3892\/or.2022.8378","volume":"48","author":"Z Chen","year":"2022","unstructured":"Chen Z, Zhang M, Lu Y, Ding T, Liu Z, Liu Y, et al. Overexpressed lncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX\/miR\u20114429\/UBE2C axis. Oncol Rep. 2022;48(3):163.","journal-title":"Oncol Rep"},{"issue":"1","key":"10230_CR11","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202502690RR","volume":"40","author":"J Cheng","year":"2026","unstructured":"Cheng J, Liu Y, Mo L, Zeng F, Na Z, Yang B, et al. UBE2C\/PTTG1 regulates PANoptosis, ferroptosis, and autophagy to improve renal ischemia\u2013reperfusion injury. FASEB J. 2026;40(1):e71398.","journal-title":"FASEB J"},{"issue":"4","key":"10230_CR12","volume":"9","author":"C-P Chou","year":"2014","unstructured":"Chou C-P, Huang N-C, Jhuang S-J, Pan H-B, Peng N-J, Cheng J-T, et al. Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions. PLoS ONE. 2014;9(4):e93934.","journal-title":"PLoS ONE"},{"key":"10230_CR13","volume":"27","author":"J Dai","year":"2021","unstructured":"Dai J, Zhou N, Wu R, Du J, Miao S, Gong K, et al. LncRNA MALAT1 regulating lung carcinoma progression via the miR-491-5p\/UBE2C axis. Pathol Oncol Res. 2021;27:610159.","journal-title":"Pathol Oncol Res"},{"issue":"9","key":"10230_CR14","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3390\/ijms20092228","volume":"20","author":"H Dastsooz","year":"2019","unstructured":"Dastsooz H, Cereda M, Donna D, Oliviero S. A Comprehensive Bioinformatics Analysis of UBE2C in Cancers. Int J Mol Sci. 2019;20(9):2228.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10230_CR15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","volume":"10","author":"D Dibitetto","year":"2024","unstructured":"Dibitetto D, Widmer CA, Rottenberg S. PARPi, BRCA, and gaps: controversies and future research. Trends Cancer. 2024;10(9):857\u201369.","journal-title":"Trends Cancer"},{"key":"10230_CR16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-biochem-061516-044908","volume":"86","author":"I Dikic","year":"2017","unstructured":"Dikic I. Proteasomal and autophagic degradation systems. Annu Rev Biochem. 2017;86:193\u2013224.","journal-title":"Annu Rev Biochem"},{"issue":"21","key":"10230_CR17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115792","volume":"24","author":"S Domentean","year":"2023","unstructured":"Domentean S, Paisana E, Casc\u00e3o R, Faria CC. Role of UBE2C in brain cancer invasion and dissemination. Int J Mol Sci. 2023;24(21):15792.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10230_CR18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.molcel.2013.01.001","volume":"49","author":"C Escribano-D\u00edaz","year":"2013","unstructured":"Escribano-D\u00edaz C, Orthwein A, Fradet-Turcotte A, Xing M, Young JTF, Tk\u00e1\u010d J, et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell. 2013;49(5):872\u201383.","journal-title":"Mol Cell"},{"issue":"7","key":"10230_CR19","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202052242","volume":"22","author":"ES Fischer","year":"2021","unstructured":"Fischer ES, Yu CWH, Bellini D, McLaughlin SH, Orr CM, Wagner A, et al. Molecular mechanism of Mad1 kinetochore targeting by phosphorylated Bub1. EMBO Rep. 2021;22(7): e52242.","journal-title":"EMBO Rep."},{"issue":"6","key":"10230_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0054-6","volume":"7","author":"J Guo","year":"2018","unstructured":"Guo J, Wu Y, Du J, Yang L, Chen W, Gong K, et al. Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression. Oncogenesis. 2018;7(6):49.","journal-title":"Oncogenesis"},{"key":"10230_CR21","doi-asserted-by":"crossref","unstructured":"Guo Y, Chen X, Zhang X, Hu X. UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb. Front Oncol. 2023;13:992233.","DOI":"10.3389\/fonc.2023.992233"},{"key":"10230_CR22","doi-asserted-by":"crossref","unstructured":"Gupta I, Singh K, Varshney NK, Khan S. Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis. Front Cell Dev Biol. 2018;6:11.","DOI":"10.3389\/fcell.2018.00011"},{"issue":"1","key":"10230_CR23","doi-asserted-by":"publisher","first-page":"15751","DOI":"10.1038\/ncomms15751","volume":"8","author":"K Ha","year":"2017","unstructured":"Ha K, Ma C, Lin H, Tang L, Lian Z, Zhao F, et al. The anaphase promoting complex impacts repair choice by protecting ubiquitin signalling at DNA damage sites. Nat Commun. 2017;8(1):15751.","journal-title":"Nat Commun"},{"issue":"2","key":"10230_CR24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3892\/or.2015.4049","volume":"34","author":"Q Han","year":"2015","unstructured":"Han Q, Zhou C, Liu F, Xu G, Zheng R, Zhang X. MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer. Oncol Rep. 2015;34(2):877\u201383.","journal-title":"Oncol Rep"},{"issue":"3","key":"10230_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s13277-011-0291-1","volume":"33","author":"Z Hao","year":"2012","unstructured":"Hao Z, Zhang H, Cowell J. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biol. 2012;33(3):723\u201330.","journal-title":"Tumor Biol"},{"issue":"18","key":"10230_CR26","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1002\/cam4.2630","volume":"8","author":"J Hu","year":"2019","unstructured":"Hu J, Wu X, Yang C, Rashid K, Ma C, Hu M, et al. Anticancer effect of icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C. Cancer Med. 2019;8(18):7833\u201345.","journal-title":"Cancer Med"},{"key":"10230_CR27","volume":"154","author":"Q Hu","year":"2025","unstructured":"Hu Q, Wang K, Chen C, Ding J, He Y, Ji Z. UBE2C promotes cell cycle progression and suppresses DNA damage-induced apoptosis in triple-negative breast cancer. DNA Repair. 2025;154:103901.","journal-title":"DNA Repair"},{"issue":"1","key":"10230_CR28","volume":"15","author":"S Huang","year":"2024","unstructured":"Huang S, Li X. UBE2C promotes LUAD progression by ubiquitin-dependent degradation of p53 to inactivate the p53\/p21 signaling pathway. Discov Oncol. 2024;15(1):589.","journal-title":"Discov Oncol"},{"issue":"1","key":"10230_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ijc.22605","volume":"121","author":"K Ieta","year":"2007","unstructured":"Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007;121(1):33\u20138.","journal-title":"Int J Cancer"},{"issue":"4","key":"10230_CR30","volume":"7","author":"P Jalali","year":"2024","unstructured":"Jalali P, Samii A, Rezaee M, Shahmoradi A, Pashizeh F, Salehi Z. UBE2C: a pan\u2010cancer diagnostic and prognostic biomarker revealed through bioinformatics analysis. Cancer Rep. 2024;7(4):e2032.","journal-title":"Cancer Rep"},{"issue":"18","key":"10230_CR31","doi-asserted-by":"crossref","first-page":"10469","DOI":"10.1093\/nar\/gkac808","volume":"50","author":"S-Y Jeong","year":"2022","unstructured":"Jeong S-Y, Hariharasudhan G, Kim M-J, Lim J-Y, Jung SM, Choi E-J, et al. SIAH2 regulates DNA end resection and replication fork recovery by promoting CtIP ubiquitination. Nucleic Acids Res. 2022;50(18):10469\u201386.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10230_CR32","doi-asserted-by":"crossref","first-page":"NP161","DOI":"10.1177\/01455613221134408","volume":"102","author":"L Ji","year":"2023","unstructured":"Ji L, Piao L, Gu X, Xiao F, Hua Q, Wu J. Silencing PARP-1 binding protein Inhibits Cell Migration and Invasion via Suppressing UBE2C in Nasopharyngeal Cancer Cells. Ear Nose Throat J. 2023;102(4):NP161-8.","journal-title":"Ear Nose Throat J"},{"key":"10230_CR33","volume":"9","author":"X Jiang","year":"2021","unstructured":"Jiang X, Yuan Y, Tang L, Wang J, Liu Q, Zou X, et al. Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3\/lncRNA-SNHG1\/miRNA-140-3p\/UBE2C axis. Front Cell Dev Biol. 2021;9:765772.","journal-title":"Front Cell Dev Biol"},{"issue":"Pt 2","key":"10230_CR34","volume":"276","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Liu B, Fu L, Li F. UBE2C regulates the KEAP1\/NRF2 signaling pathway to promote the growth of gastric cancer by inhibiting autophagy. Int J Biol Macromol. 2024;276(Pt 2):134011.","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"10230_CR35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbrc.2019.12.064","volume":"523","author":"Z Jin","year":"2020","unstructured":"Jin Z, Zhao X, Cui L, Xu X, Zhao Y, Younai F, et al. UBE2C promotes the progression of head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 2020;523(2):389\u201397.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10230_CR36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.21037\/tcr-2025-2000","volume":"15","author":"Y Kang","year":"2026","unstructured":"Kang Y, Wang J, Li Y, Yang J. SUMOylation of UBE2C facilitates hepatocellular carcinoma proliferation and invasion via the MAPK pathway. Transl Cancer Res. 2026;15(1):50.","journal-title":"Transl Cancer Res"},{"issue":"3","key":"10230_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-022-06531-5","volume":"192","author":"Y Kariri","year":"2022","unstructured":"Kariri Y, Toss MS, Alsaleem M, Elsharawy KA, Joseph C, Mongan NP, et al. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer. Breast Cancer Res Treat. 2022;192(3):529\u201339.","journal-title":"Breast Cancer Res Treat"},{"key":"10230_CR38","volume":"9","author":"Y-J Kim","year":"2020","unstructured":"Kim Y-J, Lee G, Han J, Song K, Choi J-S, Choi Y-L, et al. UBE2C overexpression aggravates patient outcome by promoting estrogen-dependent\/independent cell proliferation in early hormone receptor-positive and HER2-negative breast cancer. Front Oncol. 2020;9:1574.","journal-title":"Front Oncol"},{"issue":"9","key":"10230_CR39","volume":"24","author":"S-Y Koo","year":"2023","unstructured":"Koo S-Y, Park E-J, Noh H-J, Jo S-M, Ko B-K, Shin H-J, et al. Ubiquitination links DNA damage and repair signaling to cancer metabolism. Int J Mol Sci. 2023;24(9):8441.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10230_CR40","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.15252\/embj.201489017","volume":"33","author":"L Lafranchi","year":"2014","unstructured":"Lafranchi L, de Boer HR, de Vries EGE, Ong S-E, Sartori AA, van Vugt MATM. APC\/C(Cdh1) controls CtIP stability during the cell cycle and in response to DNA damage. EMBO J. 2014;33(23):2860\u201379.","journal-title":"EMBO J"},{"key":"10230_CR41","doi-asserted-by":"crossref","unstructured":"Lei H, Wang K, Jiang T, et al. KIAA0101 and UbcH10 interact to regulate non-small cell lung cancer cell proliferation by disrupting the function of the spindle assembly checkpoint. BMC Cancer. 2020;20(1):957.","DOI":"10.1186\/s12885-020-07463-3"},{"key":"10230_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-4-2","volume":"4","author":"M Li","year":"2009","unstructured":"Li M, Zhang P. The function of APC\/CCdh1 in cell cycle and beyond. Cell Div. 2009;4:2.","journal-title":"Cell Div"},{"issue":"2","key":"10230_CR43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbrc.2019.12.058","volume":"523","author":"J Li","year":"2020","unstructured":"Li J, Zhi X, Shen X, Chen C, Yuan L, Dong X, et al. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1. Biochem Biophys Res Commun. 2020;523(2):434\u201340.","journal-title":"Biochem Biophys Res Commun"},{"key":"10230_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08634-6","volume":"21","author":"R Li","year":"2021","unstructured":"Li R, Pang X-F, Huang Z-G, Yang L-H, Peng Z-G, Ma J, et al. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis. BMC Cancer. 2021;21:996.","journal-title":"BMC Cancer"},{"issue":"13","key":"10230_CR45","volume":"14","author":"J Li","year":"2022","unstructured":"Li J, Sun Y, Zhi X, Li Q, Yao L, Chen M. The expression and role analysis of methylation-regulated differentially expressed gene UBE2C in pan-cancer, especially for HGSOC. Cancers (Basel). 2022;14(13):3121.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10230_CR46","first-page":"7397","volume":"15","author":"X Li","year":"2023","unstructured":"Li X, Ma Z, Mei L. Comprehensive analysis of UBE2C expression and its potential roles and mechanisms in hepatocellular carcinoma. Aging (Albany NY). 2023;15(15):7397\u2013407.","journal-title":"Aging (Albany NY)"},{"issue":"21","key":"10230_CR47","volume":"24","author":"K Liang","year":"2023","unstructured":"Liang K, Wang Q, Qiu L, Gong X, Chen Z, Zhang H, et al. Combined inhibition of UBE2C and PLK1 reduce cell proliferation and arrest cell cycle by affecting ACLY in pan-cancer. Int J Mol Sci. 2023;24(21):15658.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10230_CR48","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1002\/mco2.736","volume":"5","author":"Y Liao","year":"2024","unstructured":"Liao Y, Zhang W, Liu Y, Zhu C, Zou Z. The role of ubiquitination in health and disease. MedComm. 2024;5(10):e736.","journal-title":"MedComm"},{"issue":"24","key":"10230_CR49","doi-asserted-by":"crossref","first-page":"21913","DOI":"10.1074\/jbc.M109398200","volume":"277","author":"Y Lin","year":"2002","unstructured":"Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10. J Biol Chem. 2002;277(24):21913\u201321.","journal-title":"J Biol Chem."},{"issue":"9","key":"10230_CR50","volume":"10","author":"P-F Liu","year":"2020","unstructured":"Liu P-F, Chen C-F, Shu C-W, Chang H-M, Lee C-H, Liou H-H, et al. UBE2C is a potential biomarker for tumorigenesis and prognosis in tongue squamous cell carcinoma. Diagnostics. 2020a;10(9): 674.","journal-title":"Diagnostics"},{"issue":"2","key":"10230_CR51","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1541-7786.MCR-19-0561","volume":"18","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zhao R, Chi S, Zhang W, Xiao C, Zhou X, et al. UBE2C is upregulated by estrogen and promotes epithelial\u2013mesenchymal transition via p53 in endometrial cancer. Mol Cancer Res. 2020b;18(2):204\u201315.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10230_CR52","first-page":"20230757","volume":"18","author":"J Long","year":"2023","unstructured":"Long J, Zhu B, Tian T, Ren L, Tao Y, Zhu H, et al. Activation of UBEC2 by transcription factor MYBL2 affects DNA damage and promotes gastric cancer progression and cisplatin resistance. Open Med (Wars) Warsaw, Poland. 2023;18(1):20230757.","journal-title":"Open Med (Wars). Warsaw, Poland"},{"issue":"20","key":"10230_CR53","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1097\/CM9.0000000000001708","volume":"134","author":"Z-N Lu","year":"2021","unstructured":"Lu Z-N, Song J, Sun T-H, Sun G. UBE2C affects breast cancer proliferation through the AKT\/mTOR signaling pathway. Chin Med J (Engl). 2021;134(20):2465\u201374.","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10230_CR54","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.7150\/ijbs.84067","volume":"19","author":"Z Lv","year":"2023","unstructured":"Lv Z, Wang M, Hou H, Tang G, Xu H, Wang X, et al. FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C\/mTOR signaling pathway. Int J Biol Sci. 2023;19(11):3293\u2013306.","journal-title":"Int J Biol Sci"},{"issue":"47","key":"10230_CR55","doi-asserted-by":"crossref","first-page":"18337","DOI":"10.1074\/jbc.RA118.003975","volume":"293","author":"Z Lv","year":"2018","unstructured":"Lv Z, Williams KM, Yuan L, Atkison JH, Olsen SK. Crystal structure of a human ubiquitin E1-ubiquitin complex reveals conserved functional elements essential for activity. J Biol Chem. 2018Nov 23;293(47):18337\u201352.","journal-title":"J Biol Chem."},{"issue":"3","key":"10230_CR56","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3892\/ol.2016.4171","volume":"11","author":"R Ma","year":"2016","unstructured":"Ma R, Kang X, Zhang G, Fang F, Du Y, Lv H. High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma. Oncol Lett. 2016;11(3):2300\u20134.","journal-title":"Oncol Lett"},{"issue":"9","key":"10230_CR57","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00018-014-1781-2","volume":"72","author":"JE McKeon","year":"2015","unstructured":"McKeon JE, Sha D, Li L, Chin L-S. Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system. Cell Mol Life Sci. 2015;72(9):1811\u201324.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10230_CR58","volume":"5","author":"E Paisana","year":"2023","unstructured":"Paisana E, Casc\u00e3o R, Cust\u00f3dia C, Qin N, Picard D, Pauck D, et al. UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease. Neuro-Oncol Adv. 2023;5(1):vdad048.","journal-title":"Neuro-Oncol Adv"},{"key":"10230_CR59","volume":"908","author":"B Pan","year":"2021","unstructured":"Pan B, Yin S, Peng F, Liu C, Liang H, Su J, et al. Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway. Eur J Pharmacol. 2021;908:174399.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10230_CR60","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molcel.2017.04.013","volume":"66","author":"A Paul","year":"2017","unstructured":"Paul A, Wang B. RNF8- and Ube2S-dependent ubiquitin lysine 11-linkage modification in response to DNA damage. Mol Cell. 2017;66(4):458-472.e5.","journal-title":"Mol Cell"},{"issue":"9","key":"10230_CR61","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.tibs.2019.03.011","volume":"44","author":"M Petropoulos","year":"2019","unstructured":"Petropoulos M, Champeris Tsaniras S, Taraviras S, Lygerou Z. Replication licensing aberrations, replication stress, and genomic instability. Trends Biochem Sci. 2019;44(9):752\u201364.","journal-title":"Trends Biochem Sci"},{"key":"10230_CR62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.dnarep.2018.08.003","volume":"71","author":"DH Phillips","year":"2018","unstructured":"Phillips DH. Mutational spectra and mutational signatures: insights into cancer aetiology and mechanisms of DNA damage and repair. DNA Repair. 2018;71:6\u201311.","journal-title":"DNA Repair"},{"issue":"1","key":"10230_CR63","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2605383","volume":"41","author":"L Pirone","year":"2026","unstructured":"Pirone L, Fiorillo B, Del Gatto A, Russo R, Guarracino A, Cassiano C, et al. Identification of the first peptide inhibitor of UBE2C enzymatic activity: insights from metadynamics-guided folding and binding studies. J Enzyme Inhib Med Chem. 2026;41(1):2605383.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10230_CR64","doi-asserted-by":"crossref","unstructured":"Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366(6467):818-822.","DOI":"10.1126\/science.aax3769"},{"issue":"95","key":"10230_CR65","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.biopha.2017.08.095","volume":"1","author":"T Qin","year":"2017","unstructured":"Qin T, Huang G, Chi L, Sui S, Song C, Li N, et al. Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1. Biomed Pharmacother. 2017;1(95):649\u201355.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10230_CR66","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13402-013-0150-8","volume":"36","author":"A Rawat","year":"2013","unstructured":"Rawat A, Gopal G, Selvaluxmy G, Rajkumar T. Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. Cell Oncol. 2013;36(6):459\u201367.","journal-title":"Cell Oncol"},{"key":"10230_CR67","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020;8:564601.","journal-title":"Front Cell Dev Biol"},{"issue":"59","key":"10230_CR68","doi-asserted-by":"crossref","first-page":"99482","DOI":"10.18632\/oncotarget.20107","volume":"8","author":"J Sakata","year":"2017","unstructured":"Sakata J, Utsumi F, Suzuki S, Niimi K, Yamamoto E, Shibata K, et al. Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells. Oncotarget. 2017;8(59):99482\u201394.","journal-title":"Oncotarget"},{"issue":"1","key":"10230_CR69","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41420-021-00554-5","volume":"7","author":"EV Sazonova","year":"2021","unstructured":"Sazonova EV, Kopeina GS, Imyanitov EN, Zhivotovsky B. Platinum drugs and taxanes: can we overcome resistance? Cell Death Discov. 2021June 26;7(1):155.","journal-title":"Cell Death Discov"},{"issue":"1","key":"10230_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-192","volume":"13","author":"Z Shen","year":"2013","unstructured":"Shen Z, Jiang X, Zeng C, Zheng S, Luo B, Zeng Y, et al. High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer. 2013;13(1):192.","journal-title":"BMC Cancer"},{"issue":"22","key":"10230_CR71","volume":"39","author":"H Shi","year":"2025","unstructured":"Shi H, Deng H, Chen B, Zhu Y, Yu T. FOXM1 facilitates NSCLC tumorigenesis through the transcriptional regulation of UBE2C. FASEB J. 2025a;39(22):e71230.","journal-title":"FASEB J"},{"issue":"8","key":"10230_CR72","volume":"77","author":"H Shi","year":"2025","unstructured":"Shi H, Wang M, Zhao Q, Xu Y. ZEB1 contributes to drug resistance through canonical Wnt signaling in lung cancer. IUBMB Life. 2025b;77(8):e70053.","journal-title":"IUBMB Life"},{"issue":"5","key":"10230_CR73","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","volume":"131","author":"HL Smith","year":"2024","unstructured":"Smith HL, Willmore E, Prendergast L, Curtin NJ. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. Br J Cancer. 2024;131(5):905\u201317.","journal-title":"Br J Cancer"},{"key":"10230_CR74","volume":"811","author":"N Su","year":"2026","unstructured":"Su N, Pan Z, Feng X, Wang H, Wang L. UBE2C-orchestrated ubiquitination networks in cancer progression and therapy resistance. Biochem Biophys Res Commun. 2026;811:153550.","journal-title":"Biochem Biophys Res Commun"},{"key":"10230_CR75","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.116081","volume":"170","author":"Y Tong","year":"2026","unstructured":"Tong Y, Liu Q, Zhao Z, Wang K, Wang J, Han B, et al. UBE2C-PI3K\/AKT-mediated upregulation of MTHFD2 promotes tumor progression in hepatocellular carcinoma. Int Immunopharmacol. 2026;170:116081.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10230_CR76","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","volume":"168","author":"A Tubbs","year":"2017","unstructured":"Tubbs A, Nussenzweig A. Endogenous DNA damage as a source of genomic instability in cancer. Cell. 2017;168(4):644\u201356.","journal-title":"Cell"},{"issue":"4","key":"10230_CR77","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1096\/fj.09-136259","volume":"24","author":"SJL van Wijk","year":"2010","unstructured":"van Wijk SJL, Timmers HTM. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J. 2010;24(4):981\u201393.","journal-title":"FASEB J"},{"issue":"1","key":"10230_CR78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1083\/jcb.200906147","volume":"188","author":"JH van Ree","year":"2010","unstructured":"van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM. Overexpression of the E2 ubiquitin\u2013conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol. 2010;188(1):83\u2013100.","journal-title":"J Cell Biol"},{"issue":"8","key":"10230_CR79","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202402740","volume":"7","author":"A Waltho","year":"2024","unstructured":"Waltho A, Popp O, Lenz C, Pluska L, Lambert M, D\u00f6tsch V, et al. K48- and K63-linked ubiquitin chain interactome reveals branch- and length-specific ubiquitin interactors. Life Sci Alliance. 2024;7(8):e202402740.","journal-title":"Life Sci Alliance"},{"issue":"14","key":"10230_CR80","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1158\/0008-5472.CAN-10-4576","volume":"71","author":"H Wang","year":"2011","unstructured":"Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, et al. CCI-779 inhibits cell-cycle G2\/M progression and invasion of castration resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res. 2011;71(14):4866\u201376.","journal-title":"Cancer Res"},{"issue":"4","key":"10230_CR81","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3892\/ijo.2017.3880","volume":"50","author":"R Wang","year":"2017","unstructured":"Wang R, Song Y, Liu X, Wang Q, Wang Y, Li L, et al. UBE2C induces EMT through Wnt\/\u03b2-catenin and PI3K\/Akt signaling pathways by regulating phosphorylation levels of Aurora-A. Int J Oncol. 2017;50(4):1116\u201326.","journal-title":"Int J Oncol"},{"issue":"24","key":"10230_CR82","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1111\/febs.15134","volume":"286","author":"X Wang","year":"2019","unstructured":"Wang X, Yin L, Yang L, Zheng Y, Liu S, Yang J, et al. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. FEBS J. 2019;286(24):4889\u2013909.","journal-title":"FEBS J"},{"key":"10230_CR83","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2020.11.034","volume":"534","author":"Y Wang","year":"2021","unstructured":"Wang Y, Huang F, Liu M, Zhao Q. UBE2C mRNA expression controlled by miR-300 and HuR determines its oncogenic role in gastric cancer. Biochem Biophys Res Commun. 2021a;534:597\u2013603.","journal-title":"Biochem Biophys Res Commun"},{"key":"10230_CR84","first-page":"5919","volume":"13","author":"Y Wang","year":"2021","unstructured":"Wang Y, Shi F, Tao R, Wu J, Gu J, Yang R, et al. The Relationship Between UBE2C and AGGF1 Overexpression and Tumor Angiogenesis in Non-Small Cell Lung Cancer. CMAR Dove Press. 2021b;13:5919\u201330.","journal-title":"CMAR. Dove Press"},{"key":"10230_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12212-x","volume":"24","author":"L Wang","year":"2024","unstructured":"Wang L, Zhao S, Wang Y, Liu J, Wang X. UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K\/AKT activation. BMC Cancer. 2024;24:497.","journal-title":"BMC Cancer"},{"issue":"8","key":"10230_CR86","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41420-022-00935-4","volume":"24","author":"C Xiang","year":"2022","unstructured":"Xiang C, Yan H. Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma. Cell Death Discov. 2022;24(8):130.","journal-title":"Cell Death Discov"},{"issue":"4","key":"10230_CR87","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20182384","volume":"39","author":"Y Xiong","year":"2019","unstructured":"Xiong Y, Lu J, Fang Q, Lu Y, Xie C, Wu H, et al. UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells. Biosci Rep. 2019;39(4):BSR20182384.","journal-title":"Biosci Rep"},{"issue":"1","key":"10230_CR88","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s43556-021-00043-2","volume":"2","author":"Q Yang","year":"2021","unstructured":"Yang Q, Zhao J, Chen D, Wang Y. E3 ubiquitin ligases: styles, structures and functions. Mol Biomed. 2021;2(1):23.","journal-title":"Mol Biomed"},{"issue":"32","key":"10230_CR89","first-page":"e17348","volume":"12","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li W, Yang H, Xu F, Zhang S, Cao W, et al. Inhibition of UBE2C Promotes Parkin-Mediated K63-Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer. Adv Sci (Weinh) Weinheim, Baden-Wurttemberg, Germany. 2025;12(32):e17348.","journal-title":"Adv Sci (Weinh). Weinheim, Baden-Wurttemberg, Germany"},{"issue":"6","key":"10230_CR90","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s11427-025-3233-3","volume":"69","author":"J Yang","year":"2026","unstructured":"Yang J, He M, Liao Q, Mengjiang R, Li Y, Zong C, et al. Integrating spatial and single-cell transcriptomics analysis reveals MYCN-UBE2C-TFRC signaling endows ferroptosis resistance in neuroectodermal tumors. Sci China Life Sci. 2026;69(6):1980\u201391.","journal-title":"Sci China Life Sci"},{"issue":"6","key":"10230_CR91","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.7150\/ijbs.130297","volume":"22","author":"Z Yao","year":"2026","unstructured":"Yao Z, Peng T, Dong H, Liao Y, Miao K, Qin J-J, et al. Ubiquitin-conjugating enzymes in cancer. Int J Biol Sci. 2026;22(6):3244\u201371.","journal-title":"Int J Biol Sci"},{"issue":"11","key":"10230_CR92","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrm2780","volume":"10","author":"Y Ye","year":"2009","unstructured":"Ye Y, Rape M. Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol. 2009;10(11):755\u201364.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10230_CR93","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12957-021-02344-w","volume":"19","author":"Y-Z Yu","year":"2021","unstructured":"Yu Y-Z, Mu Q, Ren Q, Xie L-J, Wang Q-T, Wang C-P. MiR-381-3p suppresses breast cancer progression by inhibition of epithelial\u2013mesenchymal transition. World J Surg Oncol. 2021;19(1):230.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10230_CR94","first-page":"22859","volume":"14","author":"P Zhan","year":"2024","unstructured":"Zhan P, Lu Y, Lu J, Cheng Y, Luo C, Yang F, et al. The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma. Sci Rep Nature Publishing Group. 2024;14(1):22859.","journal-title":"Sci Rep. Nature Publishing Group"},{"issue":"6","key":"10230_CR95","first-page":"1665","volume":"22","author":"H-Q Zhang","year":"2018","unstructured":"Zhang H-Q, Zhao G, Ke B, Ma G, Liu G-L, Liang H, et al. Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2018;22(6):1665\u201371.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10230_CR96","volume":"9","author":"J Zhang","year":"2018","unstructured":"Zhang J, Liu X, Yu G, Liu L, Wang J, Chen X, et al. UBE2C is a potential biomarker of intestinal-type gastric cancer with chromosomal instability. Front Pharmacol. 2018a;9:847.","journal-title":"Front Pharmacol"},{"issue":"2","key":"10230_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0087-3","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Zhang Z, Zhang Q, Zhang Q, Sun P, Xiang R, et al. ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. Cell Death Dis. 2018b;9(2):57.","journal-title":"Cell Death Dis"},{"issue":"4","key":"10230_CR98","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162434","volume":"133","author":"S Zhang","year":"2023","unstructured":"Zhang S, You X, Zheng Y, Shen Y, Xiong X, Sun Y. The UBE2C\/CDH1\/DEPTOR axis is an oncogene and tumor suppressor cascade in lung cancer cells. J Clin Invest. 2023a;133(4):e162434.","journal-title":"J Clin Invest"},{"issue":"20","key":"10230_CR99","volume":"102","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li X, Gong Y, Du D, Chen H, Liu L, et al. Aberrant expression of UBE2C in endometrial cancer and its correlation to epithelial mesenchymal transition. Medicine (Baltimore). 2023b;102(20):e33834.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10230_CR100","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00432-012-1275-2","volume":"138","author":"L Zhao","year":"2012","unstructured":"Zhao L, Jiang L, Wang L, He J, Yu H, Sun G, et al. UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer. J Cancer Res Clin Oncol. 2012;138(11):1951\u201361.","journal-title":"J Cancer Res Clin Oncol"},{"key":"10230_CR101","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2147\/OTT.S485053","volume":"17","author":"M Zhao","year":"2024","unstructured":"Zhao M, Li J, Wang R, Mi L, Gu Y, Chen R, et al. Ubiquitination-binding enzyme 2C is associated with cancer development and prognosis and is a potential therapeutic target. Onco Targets Ther. 2024;17:1159\u201371.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"10230_CR102","first-page":"916","volume":"56","author":"K Zhou","year":"2024","unstructured":"Zhou K, Wang D, Du X, Feng X, Zhu X, Wang C. UBE2C enhances temozolomide resistance by regulating the expression of p53 to induce aerobic glycolysis in glioma. Acta Biochim Biophys Sin (Shanghai). 2024;56(6):916\u201326.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"10230_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-021-00555-y","volume":"11","author":"M Zhu","year":"2021","unstructured":"Zhu M, Wu M, Bian S, Song Q, Xiao M, Huang H, et al. DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT\/mTOR signaling and UBE2C-mediated P53 ubiquitination. Cell Biosci. 2021;11(1):42.","journal-title":"Cell Biosci"}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-026-10230-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-026-10230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-026-10230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:58:39Z","timestamp":1792061919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-026-10230-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10230"],"URL":"https:\/\/doi.org\/10.1007\/s10565-026-10230-y","relation":{},"ISSN":["1573-6822"],"issn-type":[{"value":"1573-6822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"117"}}